BMEA

Biomea is a clinical-stage diabetes/obesity company with no product revenue and an accumulated deficit of $449M. The headline 'improvement' — net loss narrowing from $138M (FY2024) to $61.8M (FY2025, +55.4% YoY) — is not operating leverage; it's retrenchment. R&D expense fell 47.5% to $62.0M as management wound down its oncology programs (BMF-500/FLT3) and concentrated resources on metabolic disease. Cutting research spend by nearly half is survival behavior at a company whose only value is its pipeline, not a sign of a maturing business.

The disqualifying fact is the balance sheet against the burn. The MD&A states existing cash and equivalents ($55.8M at 12/31/25) 'without any future financing, will only be sufficient to fund our operations into the first quarter of 2027' — roughly nine months from today. Operating cash burn was $70.4M in FY2025 and management explicitly expects expenses to 'increase substantially' as it runs two Phase II icovamenib trials plus the BMF-650 Phase I. That math forces a capital raise well before any pivotal data, and with the stock at $1.39 — near penny-stock levels — any equity raise is heavily dilutive. Shares outstanding already grew 92.4% YoY to 72.3M, so existing holders have just been halved once and face it again.